The S&P/ASX 200 Index (ASX: XJO) is back on form and racing higher on Thursday. In afternoon trade, the benchmark index is up 1.05% to 8,939.4 points.
Four ASX shares that are rising more than most today are listed below. Here's why they are climbing:
Bravura Solutions Ltd (ASX: BVS)
The Bravura Solutions share price is up a further 11% to $3.33. Investors have been buying the wealth management software solutions provider's shares this week following the release of a guidance update. Bravura revealed that it now expects FY 2026 revenue to be between $265 million and $275 million. This is ahead of its previous guidance for revenue in line with last year's result of $256.8 million. Also upgraded was its EBITDA guidance, which is now expected to be between $55 million and $65 million. This compares favourably to its previous guidance of $50 million. Management advised that this upgrade was driven by continued strength in the British pound, higher levels of project revenue, and its continued focus on operational efficiency.
Dateline Resources Ltd (ASX: DTR)
The Dateline Resources share price is up 12% to 56 cents. This follows the release of a drilling update from the gold and rare earths explorer this morning. Managing director, Stephen Baghdadi, commented: "This is an exciting phase for Dateline as we ramp up a major drill program at Colosseum, which is instrumental in accelerating our bankable feasibility study and bringing us closer to production. By utilising our in-house diamond rig alongside Major Drilling's high-powered RC rig, we can significantly increase the pace and scope of drilling, allowing us to tackle mineral resource infill, geotechnical work, and new target testing all at once."
Orthocell Ltd (ASX: OCC)
The Orthocell share price is up 5% to $1.51. This has been driven by the release of a sales update from the regenerative medicine company. Orthocell delivered record quarterly revenue of $3 million for the quarter ended 30 September. This represents a 9.1% increase over the previous quarter, which marks the sixth consecutive quarter of record revenue. This was driven primarily by increasing market penetration of nerve repair product Remplir in Australia and Singapore.
Race Oncology Ltd (ASX: RAC)
The Race Oncology share price is up 40% to $4.35. Investors have been fighting to get hold of this biopharmaceutical company's shares after it released positive cancer research data. Managing Director, Dr Daniel Tillett, said: "The discovery (E,E)-bisantrene acts primarily by binding to G4-DNA and RNA structures, and not like the chemotherapeutic doxorubicin, fundamentally changes our thinking on how to best use this drug in the clinic. Bisantrene continues to surprise, and we look forward to building on this mechanism of action discovery in our future clinical and commercial plans."
